2024-03-21 18:57:54 ET
Summary
- RLMD plans to report results from the phase 3 Reliance II study of REL-1017, as an adjunctive treatment for major depressive disorder, in H2 2024.
- The current timeline for completion of enrolment in Reliance II may suggest a slight slippage, but my position on the potential for a run up is unchanged.
- RLMD notes it has cash to complete its current studies Reliance II and Relight, as well as a phase 1 study of modified release psilocybin.
...
Read the full article on Seeking Alpha
For further details see:
Relmada Therapeutics: Run Up Into Results May Resume Following This Drop